Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Completed × Samarium-153 × Clear all
NCT00551525 2017-07-25

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Radiation Therapy Oncology Group

Phase 2 Completed
67 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡